|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brugger W, Triller N, Blasinska-Morawiec
M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R,
Ward C, Mayne K, et al: Prospective molecular marker analyses of
EGFR and KRAS from a randomized, placebo-controlled study of
erlotinib maintenance therapy in advanced non-small-cell lung
cancer. J Clin Oncol. 29:4113–4120. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liang W, Wu X, Fang W, Zhao Y, Yang Y, Hu
Z, Xue C, Zhang J, Zhang J, Ma Y, et al: Network meta-analysis of
erlotinib, gefitinib, afatinib and icotinib in patients with
advanced non-small-cell lung cancer harboring EGFR mutations. PLoS
One. 9:e852452014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zheng Z, Jin X, Lin B, Su H, Chen H, Fei
S, Zhao L, Deng X, Xie D and Xie C: Efficacy of second-line
tyrosine kinase inhibitors in the treatment of metastatic advanced
non-small-cell lung cancer harboring exon 19 and 21 EGFR mutations.
J Cancer. 8:597–605. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ahn S, Hwang SH, Han J, Choi YL, Lee SH,
Ahn JS, Park K, Ahn MJ and Park WY: Transformation to small cell
lung cancer of pulmonary adenocarcinoma: Clinicopathologic analysis
of six cases. J Pathol Transl Med. 50:258–263. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee JK, Lee J, Kim S, Kim S, Youk J, Park
S, An Y, Keam B, Kim DW, Heo DS, et al: Clonal history and genetic
predictors of transformation into small-cell carcinomas from lung
adenocarcinomas. J Clin Oncol. 35:3065–3074. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nicholson AG, Chansky K, Crowley J,
Beyruti R, Kubota K, Turrisi A, Eberhardt WE, van Meerbeeck J and
Rami-Porta R; Staging and Prognostic Factors Committee, Advisory
Boards, and Participating Institutions; Staging and Prognostic
Factors Committee Advisory Boards and Participating Institutions, :
The international association for the study of lung cancer lung
cancer staging project: Proposals for the revision of the clinical
and pathologic staging of small cell lung cancer in the forthcoming
eighth edition of the TNM classification for lung cancer. J Thorac
Oncol. 11:300–311. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pelosi G, Fabbri A, Bianchi F, Maisonneuve
P, Rossi G, Barbareschi M, Graziano P, Cavazza A, Rekhtman N,
Pastorino U, et al: ΔNp63 (p40) and thyroid transcription factor-1
immunoreactivity on small biopsies or cellblocks for typing
non-small cell lung cancer: A novel two-hit, sparing-material
approach. J Thorac Oncol. 7:281–290. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gerdes J, Li L, Schlueter C, Duchrow M,
Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E and Flad HD:
Immunobiochemical and molecular biologic characterization of the
cell proliferation-associated nuclear antigen that is defined by
monoclonal antibody Ki-67. Am J Pathol. 138:867–873.
1991.PubMed/NCBI
|
|
13
|
Brown AF, Sirohi D, Fukuoka J, Cagle PT,
Policarpio-Nicolas M, Tacha D and Jagirdar J: Tissue-preserving
antibody cocktails to differentiate primary squamous cell
carcinoma, adenocarcinoma, and small cell carcinoma of lung. Arch
Pathol Lab Med. 137:1274–1281. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Watanabe S, Sone T, Matsui T, Yamamura K,
Tani M, Okazaki A, Kurokawa K, Tambo Y, Takato H, Ohkura N, et al:
Transformation to small-cell lung cancer following treatment with
EGFR tyrosine kinase inhibitors in a patient with lung
adenocarcinoma. Lung Cancer. 82:370–372. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Niederst MJ, Sequist LV, Poirier JT,
Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN,
Moran T, et al: RB loss in resistant EGFR mutant lung
adenocarcinomas that transform to small-cell lung cancer. Nat
Commun. 6:63772015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oser MG, Niederst MJ, Sequist LV and
Engelman JA: Transformation from non-small-cell lung cancer to
small-cell lung cancer: Molecular drivers and cells of origin.
Lancet Oncol. 16:e165–e172. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Okamoto I, Araki J, Suto R, Shimada M,
Nakagawa K and Fukuoka M: EGFR mutation in gefitinib responsive
small-cell lung cancer. Ann Oncol. 17:1028–1029. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tatematsu A, Shimizu J, Murakami Y, Horio
Y, Nakamura S, Hida T, Mitsudomi T and Yatabe Y: Epidermal growth
factor receptor mutations in small cell lung cancer. Clin Cancer
Res. 14:6092–6096. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu HY, Sun WY, Chen B, Zhang YP, Cai JF,
Su D, Wang Z, Zheng YQ and Ma SL: Epidermal growth factor receptor
mutations in small cell lung cancer patients who received surgical
resection in China. Neoplasma. 59:100–104. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen B, Hu B, Li W and Xue J:
Transformation from NSCLC to SCLC: When did it happen? Lancet
Oncol. 16:e3092015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Engelman JA, Oser MG, Niederst MJ and
Sequist LV: Transformation from NSCLC to SCLC: When did it
happen?-Authors' reply. Lancet Oncol. 16:e309–e310. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Norkowski E, Ghigna MR, Lacroix L, Le
Chevalier T, Fadel É, Dartevelle P, Dorfmuller P and Thomas de
Montpréville V: Small-cell carcinoma in the setting of pulmonary
adenocarcinoma: New insights in the era of molecular pathology. J
Thorac Oncol. 8:1265–1271. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Y, Li XY, Tang Y, Xu Y, Guo WH, Li
YC, Liu XK, Huang CY, Wang YS and Wei YQ: Rapid increase of serum
neuron specific enolase level and tachyphylaxis of EGFR-tyrosine
kinase inhibitor indicate small cell lung cancer transformation
from EGFR positive lung adenocarcinoma? Lung Cancer. 81:302–305.
2013. View Article : Google Scholar : PubMed/NCBI
|
